Carriers of BCORL1 mutation, such as PIGA and BCOR, exhibit a lower risk of progressing to secondary myeloid neoplasms, and thus, this variant could represent a marker of immune selection without being a significant driver of myeloid malignancy [37,38]. This evidence concerns the gene BCOR and myeloid neoplasm.